louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04107415: The Effect of Yoga on Respiratory Functions, Symptom Control and Life Quality of Asthma Patients
Official title: The Effect of Yoga on Respiratory Functions, Symptom Control and Life Quality of Asthma Patients: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Yoga
Keywords: Asthma
nursing
patient
yoga
Lead sponsor: Ataturk University
Sponsor class: OTHER
First posted: 2019-09-27
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomization; participants were divided into two groups by using simple random numbers table, and then the first group which was drawn by lot method was named as the experimental group.
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study was conducted to find out the effect of yoga applied to asthma patients on the patients' respiratory functions, symptom control and quality of life.

Detailed description: While there are studies conducted with yoga on different patient groups in Turkey, no studies have been found on asthma patients specifically. For this reason, it was thought that studies are needed which will prove the effect of yoga practices in preventing and controlling symptoms of asthma patients and which will contribute to nursing literature.

Eligibility criteria: Inclusion Criteria:

* must be between 18 and 55 years old
* must be diagnosed with asthma at least for six months,
* must be living in the city centre,
* must be literate and volunteered to participated in the study, were included in the study

Exclusion Criteria:

* be participated in a regular exercise program in the last 6 months,
* be have another respiratory system disease
* be in the exacerbation period,
* have a physical disease or cognitive deficiency and a psychiatric disease diagnosis that could prevent understanding the training given,

Primary outcomes:
measure: Asthma Quality of Life Questionnaire
timeFrame: 6 week
measure: Asthma Control Test
timeFrame: 6 week
measure: Respiratory Function tests
timeFrame: 6 week
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Atatürk university nursing faculty
state: Center
Study officials:
affiliation: Ataturk Üniversty
name: Gülcan Bahçecioğlu Turan, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kavak F, Ekinci M. The Effect of Yoga on Functional Recovery Level in Schizophrenic Patients. Arch Psychiatr Nurs. 2016 Dec;30(6):761-767. doi: 10.1016/j.apnu.2016.07.010. Epub 2016 Jul 30.
citation: Bahcecioglu Turan G, Tan M. The effect of yoga on respiratory functions, symptom control and life quality of asthma patients: A randomized controlled study. Complement Ther Clin Pract. 2020 Feb;38:101070. doi: 10.1016/j.ctcp.2019.101070. Epub 2019 Oct 28.
Clinical trial NCT01035515: BIIB014 Cardiovascular Monitoring Study
Official title: A Single-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Cardiovascular Effects of Single Doses of Oral BIIB014 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Healthy subjects
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2009-12-18
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The study will examine the effects of a single dose of BIIB014 on blood pressure and haemodynamic variables in healthy volunteers over 24 hours.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female subjects
* Between the ages of 18 and 50, inclusive.
* Must have a body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive

Exclusion Criteria:

* Clinically significant abnormalities (as determined by the Investigator)
* Other unspecified reason that would make the subject unsuitable for enrollment (as determined by the Investigator)

Primary outcomes:
measure: Supine Blood pressure
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Quintiles Inc
state: Kansas
Study officials:
References:
Clinical trial NCT01355315: Enhanced External Counterpulsation
Official title: Enhanced External Counterpulsation for Ischemic Cardiomyopathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Congestive Heart Failure
Keywords: EECP
ischemic cardiomyopathy
endothelin-1
ischemia coronary artery diseases
congestive heart failure not amenable to standard procedures
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2011-05-18
Enrollment: 19
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with ischemia coronary artery diseases and congestive heart failure not amenable to standard procedures

Brief summary: Enhanced external counterpulsation (EECP) is a noninvasive circulatory assist device that has been as a treatment option for refractory angina in left ventricular (LV) dysfunction. Recently, its potential role in heart failure management has been shown. However, although the concept of EECP was introduced almost four decades ago, and despite growing evidence supporting the clinical benefit and safety of this therapeutic modality, little is firmly established regarding the mechanisms responsible for the benefit of EECP include improvement in endothelial function, promotion of coronary collateralization, enhancement of ventricular function, and peripheral effects. Therefore, the major aim of this study is to provide an alternative treatment, EECP, for those unsuitable for standard procedures, especially for patients whose heart failure was caused by repeated myocardial infarction, called ischemic cardiomyopathy (ICMP), and to evaluate the clinical outcome and the endothelial function before and after 35 hours of EECP treatment.


Eligibility criteria: Inclusion Criteria:

* The inclusion criteria is left ventricular ejection fraction (LVEF) less than 40% by means of left ventricular angiography and symptomatic mild-to-moderate heart failure (New York Heart Association \[NYHA\] functional class II-III). The patient was included if there is no suitable target for either percutaneous coronary intervention or surgical bypass grafting.

Exclusion Criteria:

* IF he/she has moderate or severe aortic regurgitation (AR), history of deep vein thrombosis, or significant arrhythmia.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05842915: The National Musculoskeletal Audit and Research Database
Official title: Developing and Testing a Musculoskeletal National Audit in Community/Primary Care
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Musculoskeletal Diseases
Keywords: Primary Care
Community
Benchmarking
Audit
Quality Improvement
Lead sponsor: Keele University
Sponsor class: OTHER
First posted: 2023-05-06
Enrollment: 22000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 22,000 adult patients (over 2-year period), aged 18+ years consulting a) a Community MSK Service or b) a First Contact Practitioner (FCP) service in primary care, for a musculoskeletal pain condition

Brief summary: Developing and testing a musculoskeletal national audit in community/primary care

Detailed description: This project aims to develop, setup and test an MSK national audit which will use patient and clinician inputted data to measure the quality of care for patients presenting in community MSK services and general practice with common MSK conditions. Secondly this project aims to use the national MSK audit information to understand and improve the quality and consistency of care for MSK patients.

Eligibility criteria: Inclusion Criteria:

(MSK Services)

* MSK service seeing adult (+18 years) set in community care
* MSK service with at least 10 WTE HCPs
* System in place for digital collection of PROM/PREM data

(FCP Services)

* FCP service seeing adult (+18 years) in primary care
* FCP service with at least 1 WTE FCP seeing MSK patients
* Use of EMIS or SYSTMONE
* Able to implement Midlands FCP template
* System in place for digital collection of PROM/PREM data

(For patients)

* +18 years
* Active phone number or verified email address to participate in the patient questionnaire
* Able to provide informed consent

Exclusion Criteria:

(MSK Services)

\* Secondary care MSK services

(For patients)

* Has declined for data to be part of research as part of consent process
* Unable to complete surveys due to health issues including severe or terminal illness, severe learning difficulties or psychological disorders

Primary outcomes:
measure: To provide a secure national MSK research database for participating MSK providers to upload their routinely collected data.
timeFrame: 12 months
Secondary outcomes:
measure: To develop a standard dashboard and reporting system that supports an ongoing automated process to analyse and present the data for quality improvement purposes.
timeFrame: 12 months
Other outcomes:
Locations:
city: Keele
country: United Kingdom
facility: Keele University
state: Staffordshire
Study officials:
References:
Clinical trial NCT05641415: Finnish Imaging of Shoulder Study
Official title: Finnish Imaging of Shoulder Study on the Prevalence of Imaging Findings of the Shoulder and Their Relevance to Clinical Symptoms in the General Population.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Shoulder Pain
Rotator Cuff Tears
Glenoid Labrum Tear
Osteo Arthritis Shoulders
Keywords: Prevalence
Imaging
Shoulder
Clinical Examination
Asymptomatic
General population
Shoulder Function
Lead sponsor: University of Helsinki
Sponsor class: OTHER
Collaborators: name: Finnish Institute for Health and Welfare
name: Helsinki University Central Hospital
First posted: 2022-12-07
Enrollment: 603
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Population-based sample

Brief summary: In the Finnish Imaging of Shoulder study we will recruit 600 participants from a nationally representative general population sample. Participants aged 40 to 75 years will be invited to a clinical visit that includes assessment of general health, shoulder history and symptoms, and bilateral clinical examination and shoulder imaging (both plain radiography and MRI). We aim to assess the prevalence of abnormal imaging findings in both asymptomatic and symptomatic individuals and explore possible risk factors for abnormal imaging findings and shoulder symptoms.


Eligibility criteria: Inclusion Criteria:

* Ambulatory
* Participation in the Health 2000 Survey
* Informed Consent

Exclusion Criteria:

* Dementia
* Terminal Cancer
* Previous shoulder joint replacement
* Contraindications for MRI

Primary outcomes:
measure: Shoulder Pain and Disability Index (SPADI)
timeFrame: At baseline
measure: Constant -Murley Score
timeFrame: At baseline
Secondary outcomes:
measure: Subjective Shoulder Value (SSV)
timeFrame: At baseline
measure: Pain NRS
timeFrame: At baseline
measure: EQ-5D-5L
timeFrame: At baseline
Other outcomes:
measure: Shoulder Magnetic Resonance Imaging (MRI)
timeFrame: At baseline
measure: Shoulder Radiography
timeFrame: At baseline
measure: Clinical Shoulder Examination
timeFrame: At baseline
measure: Hospital Anxiety and Depression Scale (HADS)
timeFrame: At baseline
measure: Pain Catastrophizing Scale (PCS)
timeFrame: At baseline
measure: Pain Self Efficacy Questionnaire (PESQ)
timeFrame: At baseline
Locations:
city: Helsinki
country: Finland
facility: Helsinki University
Study officials:
References:
citation: Ibounig T, Buchbinder R, Sillanpaa N, Ramo L, Toivonen P, Raatikainen S, Koskinen S, Harkanen T, Rissanen H, Czuba T, Paavola M, Jarvinen T, Taimela S; FIMAGE investigators. Concordance of shoulder symptoms and imaging findings: a protocol for the Finnish Imaging of Shoulder (FIMAGE) study. BMJ Open. 2023 Dec 28;13(12):e074457. doi: 10.1136/bmjopen-2023-074457.
Clinical trial NCT03158415: Parents of Young Adults With Type 1 Diabetes: An Exploratory Study
Official title: Parents of Young Adults With Type 1 Diabetes: An Exploratory Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type1diabetes
Parents
Keywords: mHealth
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: University of South Florida
First posted: 2017-05-18
Enrollment: 22
Sex: ALL
Minimum age (years): 21
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Mixed Methods Exploratory Study
Primary purpose: OTHER

Brief summary: The purpose of this mixed-methods study is to explore the lived experience of parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence, and to test the preliminary efficacy of a mobile education program to reduce parental distress.

Detailed description: As young adults with T1D navigate the transition process to independence, they often do so in partnership with their parents, who are tasked with providing support and guidance. At this time, however, no structured education program exists for these parents. In addition, little is known about their learning needs, levels of distress, and readiness to provide appropriate guidance for their emerging adult children. This represents a gap in the literature and an opportunity to undertake exploratory research to learn more about this population so that meaningful education and support can be provided.

Aim 1. To describe the lived experience and diabetes-specific educational needs of parents of young adults with type 1 diabetes who are transitioning to independence.

Aim 2. To measure the effect of a mobile diabetes education program on diabetes distress levels of parents of young adults ages 18 to 25 years who are transitioning to independence.

Eligibility criteria: Inclusion Criteria:

* (1) Ability to read and speak English
* (2) parent of a child aged ≥18 years and ≤25 years with a diagnosis with T1D
* (3) must have access to a smartphone or tablet or laptop/desktop computer with internet access.

Exclusion Criteria:

* (1) Significant medical comorbidity in the participant that could, in the opinion of the PI, affect participant's capacity to complete study follow up;
* (2) inability to read and speak English.

Primary outcomes:
measure: Lived experience
timeFrame: 1 week
Secondary outcomes:
measure: Diabetes Distress
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Anastasia Albanese-O'Neill, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06786715: Retrograde Intrarenal Surgery (RIRS) With Suction
Official title: Retrograde Intrarenal Surgery (RIRS) With Suction Using Direct in Scope Suction (DISS) Versus Flexible and Navigable Access Sheath (FANS): Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Renal Stone
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-01-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Suction has been initially used in endoscopic stone management for more than 25 years during PCNL, but the emergence of new devices applying suction through patented ureteroscopes, ureteral access sheaths (UAS) and ureteral catheters led to application of suction in URS/RIRS. The application of ureteral access sheath (UAS) in RIRS can improve surgical vision , reduce intrarenal pressure (IRP) ,and decrease postoperative infectious complications .


Eligibility criteria: Inclusion Criteria:

* Single stone
* Medium sized stone ≤ 3 cm
* Renal stone
* age group \> 18

Exclusion Criteria:

* multiple renal stones
* stone size \> 3 cm
* age group \< 18
* solitary kidney
* Obstruction distal to the stone.
* urinary tract infection

Primary outcomes:
measure: Stone free rate
timeFrame: One month
Secondary outcomes:
measure: Operatove data
timeFrame: 2 hours
measure: Post operative complication
timeFrame: 2 days
Other outcomes:
Locations:
city: Zagazig
country: Egypt
facility: Elsayed Abdelhalim
Study officials:
References:
Clinical trial NCT02416115: Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia
Official title: Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia After Gynecologic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Keywords: PONV
ramosetron
naloxone
Lead sponsor: Kyungpook National University Hospital
Sponsor class: OTHER
First posted: 2015-04-14
Enrollment: 90
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: Postoperative nausea and vomiting (PONV) is one of the most undesirable complications after general anesthesia, and may lead to increased hospital stay and health care costs. The risk factors for PONV include sex (female population), nonsmoking status, past history of motion sickness and/or previous PONV, duration of anesthesia and surgical type (particular gynecologic surgery) and postoperative use of opioids. The overall incidence of PONV has been reported to be 30% with considerable variability, but can increase up to 69%- 80% in women undergoing gynecologic surgery with general anesthesia and morphine-patient controlled analgesia (PCA). Serotonin receptor antagonists (5-HT3) have been suggested one of the first line therapies for preventing PONV because of their efficacy and few side effects compared with other antiemetics. However, despite the use of this treatment, the incidence of PONV has been reported to be between 48 % and 50%. Naloxone is a drug used to counter the effects of opioid. It was found that administration of low dose naloxone prevents opioid side effects such as nausea and pruritus without affecting analgesia or opioid requirements in patient receiving morphine PCA. It was reported that the use of two antiemetic acting at different mechanisms is better to prevent PONV than monotherapy.

Therefore, this prospective, randomized, controlled study was designed to investigate the antiemetic efficacy of combination of ramosetron and premixture of naloxone with morphine PCA after gynecologic surgery.


Eligibility criteria: Inclusion Criteria:

* Nonsmoking women (ASA physical status of I or II) scheduled for gynecologic surgery under general anesthesia and postoperative analgesia with a PCA device were included

Exclusion Criteria:

* known hypersensitivity to study medication; the use of antiemetics within 24 hours before surgery; the presence of gastrointestinal, renal, hepatic, or psychiatric disease.

Primary outcomes:
measure: The number of participants with postoperative nausea and vomiting
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00596115: Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day
Official title: Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day
Study type: EXPANDED_ACCESS
Overall status: TEMPORARILY_NOT_AVAILABLE
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: Bennett, James P., Jr., M.D., Ph.D.
Sponsor class: INDIV
Collaborators: name: University of Pittsburgh
name: University of Nebraska
First posted: 2008-01-16
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT

Brief summary: R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.


Eligibility criteria: Inclusion Criteria:

* Definite diagnosis of ALS

Exclusion Criteria:

* No prior participation in R(+)PPX clinical studies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01828515: Vilazodone for Corticosteroid-Induced Memory Impairment
Official title: Vilazodone for Corticosteroid-Induced Memory Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Memory Impairment
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
Collaborators: name: Forest Laboratories
First posted: 2013-04-10
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine whether vilazodone attenuates the memory and mood effects of corticosteroids on the human hippocampus in 24 healthy controls.

Detailed description: In animals and humans, stress and corticosteroid excess are associated with changes in hippocampal structure and functioning. These findings have important implications to the millions of patients taking prescription corticosteroids and to patients with major depressive disorder or bipolar disorder who have elevated cortisol levels and memory impairment. The investigators believe that vilazodone may be a medication that can block the effects of hydrocortisone on the human hippocampus. The investigators propose to examine whether vilazodone attenuates the effects of corticosteroids in a randomized, double-blind, placebo-controlled pilot study using a within-subject crossover design.

Eligibility criteria: Inclusion Criteria:

* Healthy men and women age 18-50 years
* Education of ≥ 12 years and baseline RAVLT total words recalled score ≥ 35 (normal baseline memory)
* BMI between 18.5-30 (not underweight or obese)

Exclusion Criteria:

* History of major psychiatric illness defined as major depressive disorder, bipolar disorder, posttraumatic stress disorder, panic disorder, schizoaffective disorder, schizophrenia, eating disorders, or drug/alcohol abuse/dependence or current tobacco use
* History of neurological disorders including seizures, brain surgery, multiple sclerosis, Parkinson's disease
* Taking CNS-acting medications within 30 days of study
* History of allergic reaction or medical contraindication to vilazodone or hydrocortisone
* Significant medical conditions (e.g., myocardial infarction, cancer, diabetes)
* Vulnerable population including pregnant or nursing women, the incarcerated, and severe cognitive disorders
* Baseline HRSD (Hamilton Rating Scale for Depression) \> 7 or current suicidal ideation or history of suicide attempt
* History of systemic Corticosteroid (CS) use or recent (past 6 months) inhaled CS use

Primary outcomes:
measure: Change From Baseline RAVLT (Rey Auditory Verbal Learning Test) Total T-Score at Day 19
timeFrame: Baseline and Day 19
Secondary outcomes:
Other outcomes:
Locations:
city: Dallas
country: United States
facility: UT Southwestern Medical Center
state: Texas
Study officials:
affiliation: UT Southwestern Medical Center
name: E. Sherwood Brown, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: